Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sir Philip Cohen Awarded £1.5 Million MRC Grant

Published: Tuesday, September 25, 2012
Last Updated: Tuesday, September 25, 2012
Bookmark and Share
University of Dundee researchers to carry out research on the mechanisms that prevent inflammatory and autoimmune diseases.

The Medical Research Council (MRC) has awarded a grant of almost £1.5million to researchers at the University of Dundee to carry out research on the mechanisms that prevent inflammatory and autoimmune diseases.

The award from the MRC’s Infections and Immunity Board has been made to Professor Sir Philip Cohen.

Sir Philip and his team have already made significant findings which have identified potential new targets for drugs to treat inflammatory and autoimmune diseases.

The MRC grant will allow Sir Philip to develop the research over the next five years.

Commenting on the award Sir Philip said, “About six years ago I decided to change the field of my research to try and understand how the innate immune system not only defends the human body against infection by bacteria and viruses, but also how the deregulation of this system can lead to chronic inflammatory and autoimmune diseases, such as Arthritis, Asthma, Colitis, Lupus, Psoriasis and Sepsis.

“I made this decision because I felt that the expertise and approaches that I had developed while solving how insulin regulates carbohydrate metabolism could be exploited to elucidate a very different biological control system that is also of great medical importance.

“Getting to grips with the complex field of immunology, with which I was previously unfamiliar, has been a huge learning experience, and I am still learning! However, over the past few years my decision to enter this field has started to pay off and my team are now making interesting discoveries that promise to revolutionize our understanding of this area.

“In particular, we have discovered key mechanisms that prevent the development of inflammatory and autoimmune diseases and which have identified attractive new targets for the development of drugs to treat these diseases.”

Sir Philip is pursuing these developments with the Drug Discovery Unit in the College of Life Sciences at Dundee, as well as with pharmaceutical collaborators.

He said that the MRC’s long-term support had been key in allowing his research to develop, particularly into this new field after a long and extremely successful career in other areas of life sciences.

“I would like to thank the MRC for setting up the MRC Protein Phosphorylation Unit at Dundee in 1990 because it is the long term core funding uniquely provided to MRC Units that enables the scientists that work in them to tackle ambitious and challenging problems without worrying about where their next research grant will come from,” said Sir Philip.

Sir Philip continued, “It would have been extremely difficult to change my research to a field in which I had no previous track record had I not been working within an MRC Unit.”

In April this year, Sir Philip stood down as Director of the Medical Research Council Protein Phosphorylation Unit at the University of Dundee to concentrate full-time on his own laboratory research.

At this point it was 21 years since Sir Philip became Director of the MRC-PPU and just over 40 years since he arrived in Dundee.

Since Philip Cohen arrived in Dundee in 1971, as well as becoming one of the world’s mostly highly cited biochemists and a leader in his field, he has been a major driving force in putting Dundee on the map in scientific terms.

Not only did he establish the MRC Protein Phosphorylation Unit, the award-winning Division of Signal Transduction Therapy (DSTT) and the Scottish Institute for Cell Signalling (SCILLS) but he also played major roles in setting up the Wellcome Trust Biocentre and the Sir James Black Centre, all at the University of Dundee.

According to information published by the Institute for Scientific Information Philadelphia, he was the UK’s 3rd most cited scientist from 1990-1999, the world’s 2nd most cited scientist in “Biology and Biochemistry” from 1992-2003 and the world’s most cited biochemist from 1999-2009.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tackling Tuberculosis With New Antibody Treatments
Researchers from the University of Dundee, King’s College London and St George’s, University of London have identified potential new means to treat tuberculosis (TB).
Monday, March 07, 2011
Study Vindicates Dual Treatment Regimen
A combination of oral and nasal steroids can significantly improve the treatment of chronic rhinosinusitis – a common and often debilitating form of sinusitis – and help avoid surgery, according to new research carried out at the University of Dundee.
Tuesday, March 01, 2011
Visualising the Problem may help to Improve Antibiotics
Researchers from the Universities of Dundee and Oxford have made a significant breakthrough in understanding how resistance to antibiotics might be overcome, by producing the first ever 3D molecular image of a key drug target and showing how drugs bind to it.
Monday, January 17, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!